Summary
No substantive, label-referenced prescribing information claims were provided for evaluation. The prompt content focuses on pricing/affordability and does not align to (or reference) FDA-approved label sections for Copiktra prescribing.
Category Scores
Accurate Statements
Unsupported Statements
Copiktra (duvelisib) is an oncology drug.
The supplied excerpts from the prescribing information do not support or address this claim; no label section excerpt for indication/oncology classification was provided.
The price of Copiktra depends on the exact product (strength and package size).
Pricing/market-access details are not supported by the provided prescribing information excerpts.
The price of Copiktra depends on the buyer (U.S. cash price vs. insurance).
Pricing details are not supported by the provided prescribing information excerpts.
The price of Copiktra depends on the access path (commercial insurance, Medicare Part D, specialty pharmacy programs, or patient assistance).
Pricing/access-path details are not supported by the provided prescribing information excerpts.
Total out-of-pocket cost can change based on deductible status, copay structure, and prior authorization.
Out-of-pocket cost mechanics are not supported by the provided prescribing information excerpts.
A commonly cited manufacturer figure for Copiktra is the list price (before rebates).
No list-price/rebates/payer-finance content is supported by the provided prescribing information excerpts.
A patient's actual cost is usually lower through negotiated discounts, rebates, and payer contracts.
No prescribing-information support for negotiated pricing/cost expectations.
Amounts from negotiated discounts, rebates, and payer contracts are typically not shown to patients at checkout.
No prescribing-information support for patient checkout display practices.
For insured patients, out-of-pocket amount is often a copay or coinsurance set by the plan.
No prescribing-information support for typical insurance cost-sharing structures.
For insured patients, specialty pharmacy dispensing rules can affect out-of-pocket cost.
No prescribing-information support for specialty pharmacy dispensing rules affecting cost.
For Medicare beneficiaries, cost depends on the Part D formulary (tier placement).
No prescribing-information support for Part D formulary/tier cost dependencies.
For Medicare beneficiaries, cost depends on whether prior authorization is required.
No prescribing-information support linking Part D cost to prior authorization requirement.
For Medicare beneficiaries, cost depends on whether the patient is in the plan's deductible/coverage gap/catastrophic phases.
No prescribing-information support for Medicare coverage phase cost mechanics.
The price shown by a patient's insurer's pharmacy benefit manager after prior authorization is approved can affect cost.
No prescribing-information support for PBM pricing display after prior authorization.
In the U.S., people usually check drug-price trackers that show list price and historical changes.
Not supported by provided prescribing information excerpts.
In the U.S., people usually check a specialty pharmacy quote for the exact package (strength and days' supply).
Not supported by provided prescribing information excerpts.
In the U.S., people usually check the price shown by the insurer's pharmacy benefit manager after prior authorization is approved.
Not supported by provided prescribing information excerpts.
Affordability options for Copiktra include insurance prior authorization and step-therapy rules (where applicable).
No prescribing-information support for payer utilization-management strategies.
Affordability options for Copiktra can include patient assistance or copay support programs, if eligible.
No prescribing-information support for patient assistance/copoly support programs.
Affordability options for Copiktra can include coverage through a specialty pharmacy that can apply negotiated pricing.
No prescribing-information support for negotiated pricing via specialty pharmacy channels.
Whether affordability/access options apply depends on insurance status, diagnosis indication covered by the plan, and eligibility criteria.
No prescribing-information support for general affordability/access determinants.
Contradictions
Important Omissions
No FDA-label-relevant prescribing information content (e.g., indications and usage, dosage/administration, contraindications, boxed warnings, warnings/precautions, drug interactions, or administration/storage instructions) was provided within the statements to enable label alignment evaluation.
Importance:
High
Although the prompt includes excerpts describing treatment-related mortality/infections and that COPIKTRA is not indicated/recommended for initial or second-line treatment, none of the provided claims address or correctly use these label elements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided statements are about pricing/affordability rather than dosage, contraindications, boxed warnings, or other direct prescribing instructions. However, because no label-relevant prescribing claims were evaluated, the alignment assessment is poor.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Statements are primarily non-label (pricing/access) and do not cite or reflect FDA-approved prescribing information sections relevant to safe prescribing.
Suggested Improvement
Provide only label-supported prescribing content (e.g., Indications and Usage; Dosage and Administration; Contraindications; Boxed Warnings; Warnings and Precautions; Drug Interactions; Use in Specific Populations) and ensure each claim is supported by the corresponding label section/excerpt.